Previous 10 | Next 10 |
Gainers: [[SEAC]] +30.3%. [[ABCL]] +13.7%. [[VSTM]] +9.7%. [[GIII]] +9.5%. [[RRR]] +8.8%.Losers: [[WVE]] -24.8%. [[SCPH]] -15.4%. [[PCVX]] -12%. [[UPC]] -9.5%. [[TDUP]] -6%. For further details see: VSTM, WVE, ABCL and SCPH among after-hours movers
scPharmaceuticals (SCPH): Q4 GAAP EPS of -$0.58 misses by $0.22.Cash, cash equivalents, restricted cash and investments of $105.3MPress Release For further details see: scPharmaceuticals EPS misses by $0.22
FUROSCIX® New Drug Application resubmission anticipated in Q3 2021 FREEDOM clinical study on track for topline results in Q3 2021 Ended Q4 with cash, cash equivalents, restricted cash and investments of $105.3 million, sufficient to fund operations through potential...
The following slide deck was published by scPharmaceuticals Inc. in conjunction with this event. For further details see: scPharmaceuticals (SCPH) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow
BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
No additional clinical efficacy, PK or safety data required December 31, 2020 cash, cash equivalents, restricted cash and investments estimated to be $105 million, sufficient to fund operations through potential FUROSCIX® approval and launch and into 2023 BURLINGTON, ...
BURLINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
BURLINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, t...
The FUROSCIX CRL issues relating to the manufacturing facilities are resolvable. Bioequivalence has been shown to already-in-use IV Lasix, so we feel comfortable assuming the risk of the unknown CRL issue. The commercial opportunity for FUROSCIX has been validated, given that IV L...
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...